Roche: Defining priorities for a high tech healthcare company
|
|
- Winfred Wilkerson
- 6 years ago
- Views:
Transcription
1 Roche: Defining priorities for a high tech healthcare company Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO October This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected 2 1
2 Performance up-date Our priorities 3 Continuing excellent growth Over CHF 3.5 billion organic sales added CHF bn % change in USD YTD Sept YTD Sept CHF local growth Pharmaceuticals Diagnostics Roche Group
3 Strong rise in Group sales and Core EPS Sales (CHF billions) % Sales +13 % +24 % +14 % +29 % +19 % Core EPS +21 % +15 % Core EPS (CHF) 0 H H H H H Historical Core EPS data 2003 to 2004 restated 5 Strategic acquisitions and portfolio enhancements Committed to technology leadership Leader in Pharma Driving personalised healthcare Leader in Diagnostics THP (therapeutic antibody technology) Alnylam (RNA interference technology) Transgene (therapeutic HPV vaccine) BioVeris (electrochemiluminescence technology) 454 Life Sciences (ultra fast gene sequencing) NimbleGen (high-density DNA microarrays) 1 Ventana (tissue-based diagnostics) 1 Tanox (acquired by Genentech) Early detection Diagnosis Patient stratification Treatment Monitoring 1 Tender offer pending 2 Acquisition not yet closed/ pending regulatory approval 6 3
4 Ventana Acquisition Complementary Technologies Complete tissue-based diagnostics capabilities for customers Pathologist Testing on Tissue Testing after Protein / Nucleic acid Extraction IHC protein markers FISH/CISH/SISH NA markers DNA mutation RNA expression via microarray RNA expression via multiple RT-PCR or mutation detection RNA expression via multiple RT-PCR or mutation detection Protein expression via IC system AmpliChip LC480 TaqMan Elecsys Ventana technology capabilities Roche Diagnostics technology capabilities 7 Ventana Acquisition Company Overview Changing the practice of medicine in tissue-based cancer diagnosis Company facts Founded 1985, based in Tucson, Arizona 952 employees (year end 2006) 2006 Financials Revenue `06: $ US 238 m Rev. CAGR 04-06: ~20 % Operating Margin: ~19 % Leader in tissue-based diagnostics Leadership in advanced staining segment Large installed base in pathology labs Strong U.S. presence Source: Ventana Investor Presentation 8 4
5 Ventana Acquisition New Market Potential Histopathology; ~1 bn market, growing 10 % p.a.* Market size and growth Key growth drivers m USD 10 % CAGR 1,600 CAGR 11 % High need for test automation and standardisation Increasing incidence of cancer Advanced / ISH/IHC Stains 11 % Targeted cancer drugs requiring companion diagnostics Primary/ Special Stains Tissue Prep 2005 A 2006* E2011* 3 % Source: Analyst reports, Roche Analysis * Analysis of the histopathology market based on Analyst forecasts 9 Growth objectives for 2007 Reconfirming improved outlook of Q1 Sales Double-digit sales growth 1 for Roche Group and Pharmaceuticals Division Above-market sales growth in both divisions Core EPS target Core earnings per share growth above sales growth 1 in local currencies barring unforeseen events 10 5
6 Performance up-date Our priorities 11 Roche Challenge # 1 Achieve above peer level sales growth for both divisions 1 Can we constantly gain market share in both divisions?
7 YTD Sept 07: Sales growth two to three times the market Growing share of key growth drivers Local sales growth Key products as % of pharma sales Division Europe North America Latin America Japan 4% 6% 7% 6% 7% 14% 12% 14% 12% 16% Roche IMS YTD July '07 70% 60% 50% 40% 30% 20% 10% 0% 2.4% 5.5% 6.5% 0.2% 1.3% 2.9% 5.3% 6.4% 8.5% 9.6% 5.6% 2.8% 6.5% 7.4% 1.3% 2.4% 3.0% 4.5% 5.7% 6.8% 2.2% 2.9% 3.1% 4.4% 5.4% 5.8% 8.9% 11.0% 11.8% 13.2% 15.5% 15.4% 14.7% 15.1% Bonviva/Boniva Tarceva Pegasys Cellcept NeoRecormon/ Epogin/Mircera / Rituxan 13 Key products on growth path New indications provide fresh growth opportunities MAT sales (CHF bn) Q1-05 Q3-05 Q1-06 Q3-06 Q1-07 Q3-07 Tarceva Q1-02 Q3-02 Q1-03 Q3-03 Q1-04 Q3-04 Q1-05 Q3-05 Q1-06 Q3-06 Q1-07 Q MAT sales (CHF bn) % % 0 Q1-05 Q3-05 Q1-06 Q3-06 Q1-07 Q3-07 Pharma Division sales Roche Pharma sales 0 Q1-02 Q3-02 Q1-03 Q3-03 Q1-04 Q3-04 Q1-05 Q3-05 Q1-06 Q3-06 Q1-07 Q3-07 MAT = Rolling 4 quarter sales at avg. YTD Sept. '07 exchange rates 14 7
8 Focus on differentiated medicines pays off A young and growing portfolio Pegasys Molecular Dx CellCept Tamiflu CHF 1 billion or more CHF 2 billion or more CHF 3 billion or more CHF 4 billion or more Rocephin RoAccutane NeoRecormon/ Epogin Centralized Diagnostics Diabetes Care CellCept Centralized Diagnostics Diabetes Care Value drivers 6 10 Sales (CHF bn) Our oncology strategy: Setting new standards of care New tumor types, new combinations, new lines of intervention Clinically differentiated product Example target all tumor types target all possible combinations target earlier (adjuvant) intervention Superior outcome for patients 3 rd line 3 rd line 3 rd line 2 nd line 2 nd line 1 st line 1 st line GIST Pancreatic 2 nd line Ovarian Adjuvant Prostate 1 st line RCC Adjuvant BC Adjuvant Completed NSCLC Ongoing CRC In preparation 16 8
9 Oncology: Many market opportunities on the horizon and addressed CRC NSCLC BC HER2+ BC HER2- RCC Adjuvant Approval Trials (mono) P3, (combo) P3 ; Tarceva P3 + (in planning) P3 ; Approval, (mono), (EU) (EU), Roferon A Metastatic 1st line Trials Filed (EU), (EU,US) line ext with oxaliplatin P3 + Tarceva, Tarceva maint. P3 + ; + pertuzumab P3 line ext. Filed (EU) Metastatic 2nd line Approval Trials (US)+ filed (EU) Tarceva P3 Tarceva+ P3 Approved Filed New market opportunities addressed 17 : Building standard of care, defending leadership Effectively maximizing a key asset Main Indication NSCLC 1 st line nonsquamous Adjuvant NSCLC 1 st line squamous 2 nd line Squamous and nonsquamous AVAiL ATLAS AVASQ BRIDGE BETA Lung ECOG 1505 Status Data presented at ASCO 2007 Initiated Q4 05 terminated Pilot study, initiated Q2 06 Initiated Q2 05 To start soon Main Indication Status mcrc 1 st line NO16966 met primary endpoint, filed Adjuvant AVANT Recruitment completed Q CC NSABP C-08 Recruitment completed Q Adjuvant rectal Ca E5204 Initiated Q1 06 RCC 1 st line AVOREN CALGB Data available Positive results Q4 06, Filing 2007 mbc 1 st line HER2- negative AVADO RIBBON-1 Recruitment completed Q2 07 Initiated Q4 05, H completion target Pancreatic Cancer 1 st line AVITA Recruitment completed Adjuvant BC 1 st line HER2- positive 2 nd line HER2- negative AVEREL ( +/-) RIBBON-2 E2104 E5103 Initiated Q3 06 Initiated Q1 06 Completed enrolment Q4 06 To initiate H2 07 Ovarian Cancer Prostate Cancer 1 st line 2 nd line Hormone refractory GOG 218 ICON7 GOG 213 CALGB Initiated Q3 05 Initiated Q4 06 In preparation Initiated Q2 05 HER2- positive * Formerly called AVAIL BEATRICE BETH To initiate H2 07 In preparation NHL aggr. R_CHOP +/- To start in Q
10 / Tarceva/ / : Maximizing across the portfolio Main Indications Adjuvant CC Adjuvant BC Combo with Combo with oxaliplatin AVANT NO16968 NO Status Recruitment completed Q Recr. completed, Final analysis end 07/early 08 Recr. completed Tarceva NSCLC 1st line maintenance NSCLC 2nd line Adjuvant NSCLC Combo with chemotherapy Combo with Combo with SATURN ATLAS BETA Lung RADIANT Initiated Q4 05, Recruitment to complete 07 Initiated Q4 05, Recruitment to complete end 07 Initiated Q2 05 Initiated Q3 06 NHL maintenance 1st line After induction PRIMA Recruitment completed Q CLL 1st line ML17102 Recr. completed CLL relapsed REACH Recruitment to complete end 07 Gastric Ca ToGA Initiated Q3 05, final analysis in 2009 Adjuvant BC 1yr vs. 2yrs treatment HERA Final analysis 2008/2009, event driven 19 The key goal of all our efforts in oncology: Moving from extending life to potentially saving life Filed Ongoing adjuvant BC adjuvant CC combo adjuvant CC Adjuvant Maintenance 1 st Line 2 nd Line Tarceva adjuvant NSCLC adjuvant rectal Ca adjuvant NSCLC Tarceva & NSCLC maintenance Tarceva NSCLC maintenance inhl maintenance RCC gastric Ca mbc combo hormonal mbc 1st line ext. pancreatic Ca & mbc 1st line ext. NSCLC mcrc 1st line ext. mcrc 1st line combo NSCLC 1st line ext. ovarian Ca gastric Ca mbc 1st line CLL mcrc 2nd line combo prostate Ca Tarceva & NSCLC 2nd line mbc 2nd line relapsed CLL Starting soon adjuvant BC & adj. BC, HER2+ & aggr. NHL & Pertuzumab HER2+ mbc 20 10
11 Funding: Roche oncology products are cost-effective GBP in (000) Cost per QALY for selected drugs (UK data NICE/SMC) We aim to expand use of our products to earlierstage cancers, providing full benefit to patients st Line Follicular NHL Stage III/IV Aggressive NHL early BC Tarceva 2nd line NSCLC Statins high risk mbc Glivec CML Statins Elderly low risk 21 Oncology is still dramatically under funded Compared to other disease areas Mental disease 25.3% Total disease burden in DALYs Other 26.3% Cardiovascular 17.1% Cancer 16.7% Injuries 8.7% Resp. 5.9% Total healthcare costs Cancer 6.4% Cost breakdown in oncology (example: Germany) Inpatient hospital care 67% Drugs 8% Ambulatory 16% Other 9% Source: A pan-european comparison regarding patient access to cancer drugs, Karolinska Institute DALY: Disability-Adjusted Life Years, figures from 2002/3; Commonly used measure of the burden of disease 22 11
12 Roche has a low exposure to generics Long-term sustainable business Sales erosion due to generisation (% of 2004 sales) 100% 80% 60% Average European peers 40% 20% Roche 0% Roche has a unique investment case Roche: Unique geographic risk diversification USA (Greater) Europe Japan Asia China Latin America Roche: Unique pillars of value risk diversification Tamiflu Boniva Actemra in CRC Mircera Pegasys Tarceva in RA CellCept NeoRecormon Diabetes Care in NSCLC in BC JTT- 705 (R1658) Immuno- Diagnostics Molecular Diagnostics GLP-1 R 1583 FUTURE PILLARS 24 12
13 The short/medium term sales perspective Challenge # 1: Achieve above industry-standard sales growth Conclusion # 1: Roche wants to maximize assets on hands and to translate value opportunities into reality 25 Challenge # 2 Turn attractive top line into attractive bottom line Can we achieve an 2 attractive top-line and still deliver strong EPS growth?
14 Doing the right things right Three focus areas People are key! Activate potential and constantly educate: to learn faster than our competitors is the only sustainable factor of success! The right quantum size for Roche? Fixed cost versus variable cost Operational productivity 27 Activate our employees potential Constant education to overcome fear of change Number of employees To achieve our ambitions we have to activate the potential of our 72,000 employees! Our leadership and communications efforts have to concentrate here low Readiness for change high 28 14
15 Organizations do not grow linearly Fixed cost base grows in quantum steps The highest profitability is achieved at the top of a quantum step 29 What is the right quantum size for a sustainable Roche? Even if costs grow considerably slower than sales, there is risk that we build up too much infrastructure / fixed costs! Sales 30 15
16 Constantly improving operational productivity Operational productivity is an important key enabler for the Roche Group We must become better and cheaper in whatever we do! 31 Focus on differentiated products paying off Sales doubling, operating profits tripling Group sales 1 (CHF bn) Group operating profit 2 (CHF bn) % % 20.2% 21.3% 22.9% 25.9% Pharmaceuticals and Diagnostics 2 before exceptional items 32 16
17 Core EPS rising steadily Core EPS CAGR 1 ('02 '06): 23 % CHF Compound Annual Growth Rate Economic success translated into shareholder returns Again a substantial increase in 2006 Dividend CAGR 1 ( 91-06): 18 % CHF Compound Annual Growth Rate 1995 including centenary bonus 2006 Dividend: Proposed by the Board of Directors 1 compound annual growth rate 34 17
18 Short/medium term bottom-line perspective Challenge # 2: Achieve above industry-standard value creation Conclusion # 2: Roche has many programs running to ensure above industry standard EPS-growth 35 Challenge # 3 Filling the strategic gap Can we produce enough internal and external innovation to maintain the Roche Group s Leadership position?
19 Sustainable leadership How can we constantly provide benefit to customers? Innovation Research Development Production Marketing & Distribution Customer benefit Which degree of innovation (= medical differentiation) is necessary to jump regulatory and reimbursement hurdles? 37 The Roche hub & spoke -model: Roche controls the global value chain, but is open for Research partnerships Roche core Innovation partners Research Development Production Marketing + Distribution 38 19
20 Why do we network in the Research field? Discovery Research Development Manufacturing Marketing Selling Intellect intensive Size does not increase productivity beyond a certain critical level! Capital intensive Size is critical to optimize investment, speed and coverage! More trials More patients Investigator networks In-licensing power More launches Larger products Market entry speed Sales force flexibility Economies of scope Economies of scale: Size matters 39 Access to Innovation is key - competition growing Costs of third party innovation is raising steeply! Average cost of in-licensing (Rx), $m Early-stage Late-stage Average cost of in-licensing deals rose 40% (CAGR) since 2000 By 2010, 40% of Pharma peers revenues expected to come from external sources of innovation
21 The potential is there: unmet medical needs in many age-related diseases Met medical needs Unmet medical needs Alzheimer s Dementia Parkinson s Depression CNS RA / MS Osteoporosis CHD / Dyslipidemia Hypertension Inflammation/ Cardiovascular Bone COPD Respiratory Incontinence Urology AGE-RELATED DISEASES Diabetes T2 Cancer Stroke Endocrine Tumors Accidents/ Injuries Roche focus area 41 Current and future key sources of growth (Metastatic use) (Oncology ) Autoimmune portfolio Mircera (Renal & oncology) (Adjuvant use) Diabetes portfolio CETP inhibitor (Dyslipidemia) The coming 3 to 4 years will be decisive on how well we can fill the value propositions for beyond Illustrative 21
22 YTD Sep 2007: Autoimmune portfolio Ocrelizumab additionally developed for MS and lupus RA Phase I Phase II Phase III R7277 (RA) Toyama R1503 (RA) p38 inhib. Ocrelizumab (RA) (RA) DMARD IR Actemra (RA) Approved (RA TNF IR) All Autoimmune R7277 (RA) Toyama R3477 (MS) Actelion R1295 (MS) IFN-alpha Ab (SLE) GNE Ocrelizumab (SLE) Ocrelizumab (LN) Ocrelizumab (RRMS) (RRMS) GNE moving to ph. 3 moving to ph. 3 Ocrelizumab (RA) (PPMS) GNE ANCA avasc. GNE (SLE) GNE (RA) DMARD IR Actemra (RA) Actemra (sjia) CellCept (LN) (RA TNF IR) R3421 (AI) Biocryst (LN) GNE CellCept (PV) 43 YTD Sep 2007 Metabolism/Diabetes pipeline making good progress- major new area for Roche emerging CETP Inhibitor Phase IIb data available internally: very encouraging Torcetrapib side effects (elevated blood pressure) appear compound-specific GLP-1 phase II data available soon First phase II data (sustained release formulation) before year end Decision for phase III to be taken in early 2008 DDP-IV (3) moves into phase II Good safety profile Potential for weight reduction? 44 22
23 Roche 2015 This program provides strategic direction and aligns our priorities to fill sustainable long-term growth gap Roche: Innovation Is Our Core Scope of Innovation Innovation Capabilities Choices around where we should focus to ensure advantaged participation Choices around how we will run our Innovation Model Innovation Investment Choices around how much resources to allocate and deploy 45 Roche internal R&D 5 Disease Biology Leadership Teams responsible for the start of the value chain Today s model New model NMP TA LI LO Ph 0 Ph 1 Ph 2 Ph 3 Reg. NMP TA LI LO Ph 0 Ph 1 Ph 2 Ph 3 Reg. Site Management Committees R&D Committee LCC Disease Biology Leadership Teams (DBLT) (x5) PPG BDC Strategic Portfolio Committee Non-Clinical Drug Safety Committee Drug Safety Committee Non-Clinical Drug Safety Committee Drug Safety Committee Decision Making Committees Decision Making Committees & Peer Reviews 46 23
24 Long-term perspective Roche 2015 is a crucial platform Challenge # 3: Filling the value gap Conclusion 3: With Roche 2015 we have the right platform in place to identify the right priorities 47 We Innovate Healthcare 24
Roche: defining priorities for a high tech healthcare company
Roche: defining priorities for a high tech healthcare company Erich Hunziker, CFO and Deputy Head of the Corporate Executive Committee June 2007 1 This presentation contains certain forward-looking statements.
More informationRoche: Building on strength
Roche: Building on strength Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO 1 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More informationRoche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011
Roche Committed to innovation and profitable growth Dr. Alan Hippe CFO Roche Zurich, May 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationTranslating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals
Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain
More informationRoche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010
Roche Lazard Capital Markets 7 th Annual Healthcare Conference Thomas Kudsk Larsen, 17 November 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationRoche: Committed to Innovation. William M. Burns, CEO Roche Pharmaceuticals
Roche: Committed to Iovation William M. Burns, CEO Roche Pharmaceuticals This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such
More informationRoche A sustainable business model based on innovation and productivity gains. Karl Mahler, Head of Investor Relations
Roche A sustainable business model based on innovation and productivity gains Karl Mahler, Head of Investor Relations 1 This presentation contains certain forward-looking statements. These forward-looking
More informationDr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin
Roche Positioning AVASTIN-based therapy as essential to treat cancer Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader This presentation contains certain forward-looking
More informationInnovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015
Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationRoche. Pascal Soriot COO Roche Pharmaceuticals
1 Roche Pascal Soriot COO Roche Pharmaceuticals 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche YTD September 2007 October 16, 2007
Roche YTD September 2007 October 16, 2007 October 16, 2007 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,
More informationFocus and value creation
Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationKapil Dhingra, VP,Head Oncology DBA
Lehman Global Healthcare Conference 18 March 2008, Miami Kapil Dhingra, VP,Head Oncology DBA Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking
More informationRoche First quarter Roche First Quarter 2007 Apr. 18,
r Roche First quarter 2007 April 18, 2007 Apr. 18, 2007 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationClinical Development at Roche: Driving the paradigm shift
Clinical Development at Roche: Driving the paradigm shift Jean-Jacques Garaud, MD Global Head Pharma Development, Chief Medical Officer Roche UBS Global Life Science Conference, New York, September 22,
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationRoche: Committed to Innovation
Roche: Committed to Innovation William M. Burns CEO Roche Pharmaceuticals UBS Swiss Equity Conference, Zurich, 26. November 2009 This presentation contains certain forward-looking statements. These forward-looking
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationBasel, October 17, 2006
Roche Third quarter 2006 Basel, October 17, 2006 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationWe Innovate Healthcare
We Innovate Healthcare 1 Roche Pharma Development Daniel L. Zabrowski Head of Pharma Development Operations Sanford Bernstein, London, September 27th, 2006 2 This presentation contains certain forward-looking
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationRoche at a Glance An Introduction to our Company. February 2013
Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationNine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587
Media Release Basel, 3 October 20 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-2% in Swiss
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationExpanding the boundaries of nutrition Luis Cantarell
Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationFood & Beverages Food for a growing world
Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill
More informationGuido Magni Global Head of Medical Sciences
Roche Pharma Development Guido Magni Global Head of Medical Sciences Sellsider Breakfast, Paris, September 5th, 2006 1 This presentation contains certain forward-looking statements. These forward-looking
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationInvestor Update. Roche in 2011: Strong results and positive outlook. Basel, 1 February 2012
Investor Update Basel, February 0 Roche in : Strong results and positive outlook Group sales rise % (-0% in Swiss francs; +6% in US dollars), excluding Tamiflu. Significant foreign exchange impact of percentage
More informationRoche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance
Media Release Basel, 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER 1 to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationPartnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationSales CHF millions As % of sales % change. In CHF Group sales 12,942 12,
Investor Update Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationHuman Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS
Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO January 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationMERCK KGAA, DARMSTADT, GERMANY
MERCK KGAA, DARMSTADT, GERMANY 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Belén Garijo, CEO Healthcare Udit Batra, CEO Life Science San Francisco January 7, 2019 Disclaimer Publication of Merck KGaA,
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationIpsen Oddo BHF Forum January 12, 2018
Ipsen Oddo BHF Forum 2018 January 12, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationRoche Annual Results 2008 February 2009 Basel, London, New York. Roche Full Year Results 2008 February 4, 2009
1 Roche Annual Results 2008 February 2009 Basel, London, New York This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationRoche delivers good sales growth in the first nine months of 2016
Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More information